Over 4,000 delegates attended the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco, 13-15 February 2020. The International Kidney Cancer Coalition (IKCC) was present with a booth to raise awareness, and also attended many of the medical and patient advocacy sessions.
The past couple of years have been watershed years for kidney cancer due to multiple new drug approvals, particularly for immunotherapy combinations. Presentations at ASCO GU 2020 consolidated our understanding of the newly approved agents, particularly when given in combination. Highlights included results from a first in human trial of a new targeted therapy in combination with immunotherapy, the benefit of precision radiotherapy alongside immunotherapy for advanced kidney cancer, heads-up for a randomised clinical trial with a HIF-2alpha inhibitor, and the need for nephrectomy in the immunotherapy era. A randomised clinical trial for one of the first triple combination treatments of a TKI and double immunotherapy is also looking for patients in North America, Europe, Latin America and the Asia-Pacific region.